Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional

Combination Study for High Risk Multiple Myeloma Patients

ClinicalTrials.gov ID: NCT03104270

Public ClinicalTrials.gov record NCT03104270. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 12:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination With Pomalidomide, Carfilzomib and Dexamethasone Among High Risk Relapsed/ Refractory Multiple Myeloma Patients

Study identification

NCT ID
NCT03104270
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Oncotherapeutics
Industry
Enrollment
13 participants

Conditions and interventions

Interventions

  • Elotuzumab Drug
  • Pomalidomide Drug
  • Carfilzomib Drug
  • Dexamethasone Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 12, 2017
Primary completion
Oct 24, 2019
Completion
Jan 22, 2020
Last update posted
Mar 30, 2022

2017 – 2020

United States locations

U.S. sites
6
U.S. states
3
U.S. cities
6
Facility City State ZIP Site status
California Cancer Associates for Research & Excellence (cCARE) Encinitas California 92024
Robert A. Moss, MD, FACP, Inc Fountain Valley California 92708
Pacific Cancer Care Monterey California 93940
James Berenson, MD, Inc West Hollywood California 90069
Millennium Oncology Research Clinic Pembroke Pines Florida 33024
Regional Cancer Care Associates MD LLC Bethesda Maryland 20817

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03104270, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 30, 2022 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03104270 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →